Dan O'Day, Gilead CEO (Jim Watson/AFP via Getty Images)
With more than 30 oncology partners, Gilead lays out its 2030 vision of 20 new approvals
Gilead has had a rocky history in oncology.
A brief recount of the past few quarters: Trodelvy, the crown jewel of Gilead’s $21 billion Immunomedics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
